News Conference News ESC Heart Failure 2025 HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM Todd Neale May 19, 2025
News Daily News Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM Caitlin E. Cox March 21, 2025
News Daily News Acoramidis Approved in Europe for ATTR Cardiomyopathy Michael O'Riordan February 12, 2025
News Conference News HFSA 2024 Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM L.A. McKeown October 04, 2024
News Conference News ESC 2024 HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM L.A. McKeown August 30, 2024
News Daily News Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B Michael O'Riordan June 24, 2024
News Conference News AHA 2022 CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis Yael L. Maxwell November 05, 2022
News Daily News AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More Shelley Wood December 17, 2020
News Conference News AHA 2019 AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials Shelley Wood November 11, 2019
News Conference News ESC 2018 Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy Michael O'Riordan August 27, 2018